动脉样硬化中的共刺激和共抑制免疫检查点:动脉样硬化中的治疗点?
相关实验视频
Updated: Jun 18, 2025

15:15
Flow Cytometry Analysis of Immune Cells Within Murine Aortas
Published on: July 1, 2011
34.6K
Katrin Nitz1, Joerg Herrmann1, Amir Lerman1
1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
JACC. Basic to translational science
|July 29, 2024
概括
目前用于动脉样硬化心血管疾病 (ASCVD) 的治疗方法显示益处有限. 本综述探讨免疫检查点抑制剂作为一种新的治疗策略,针对超出脂质管理的炎症,以改善心血管结果.
科学领域:
- 心血管医学 心血管医学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 目前对动脉样硬化心血管疾病 (ASCVD) 的治疗主要集中在管理诸如高脂血症等心血管风险因素上,最近的进展包括PCSK-9抑制剂.
- 新兴证据强调炎症是动脉样硬化的一个重要驱动因素,需要探索超出降脂疗法.
- 虽然针对ASCVD炎症的临床试验在患者耐受性,减少炎症标志物和改善心血管终点方面表现有希望,但最佳策略仍在调查中.
研究的目的:
- 审查基于免疫检查点的疗法作为治疗动脉样硬化心血管疾病 (ASCVD) 的新型免疫治疗策略的潜力.
- 在ASCVD治疗的背景下,讨论共刺激和共抑制免疫检查点抑制剂的应用,其中许多是FDA批准的癌症和自身免疫性疾病.
主要方法:
- 对ASCVD抗炎疗法的现有临床试验数据 (第一,第二和第三阶段) 的审查.
- 对将炎症与动脉样硬化联系起来的实验证据的分析.
- 专注于免疫检查点抑制剂 (共刺激和共抑制) 以及它们在其他疾病中的已知用途.
主要成果:
- 临床试验表明,ASCVD的免疫调节疗法通常被患者容忍得很好.
- 这些疗法已经证明减少了关键的炎症标志物.
- 一些试验表明对心血管终点有积极影响,尽管需要进一步的研究.
结论:
- 动脉样硬化是由炎症驱动的,这表明免疫疗法在传统风险因素管理之外发挥了作用.
- 免疫检查点抑制剂代表了ASCVD有前途的新疗法,利用其他疾病的现有批准.
- 需要进一步的研究来确定最佳的基于免疫的策略和ASCVD治疗患者分层.
相关概念视频
Inflammation
53.3K
Overview
53.3K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Tumor Immunotherapy
498
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
498
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Inflammatory Response
1.9K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.9K

